These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 24654703)

  • 1. Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
    Yatera K; Yamasaki K; Nishida C; Noguchi S; Oda K; Akata K; Nagata S; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
    J Asthma; 2014 Sep; 51(7):762-8. PubMed ID: 24654703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
    Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2011 Oct; 24(5):571-6. PubMed ID: 21624490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma.
    Akamatsu T; Shirai T; Kato M; Hashimoto D; Yasui H; Inui N; Suda T; Yokomura K; Hayakawa H; Ide K; Toyoshima M; Kuroishi S; Yasuda K; Suganuma H; Yamada T; Masuda M; Chida K
    Allergol Int; 2012 Jun; 61(2):323-9. PubMed ID: 22441635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
    Lee DK; Jackson CM; Currie GP; Cockburn WJ; Lipworth BJ
    Br J Clin Pharmacol; 2003 Nov; 56(5):494-500. PubMed ID: 14651722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
    Tamm M; Richards DH; Beghé B; Fabbri L
    Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
    Aalbers R
    Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
    Dal Negro RW; Micheletto C; Tognella S; Trevisan F; Guerriero M
    Eur Ann Allergy Clin Immunol; 2006 May; 38(5):153-7. PubMed ID: 17058847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formoterol and salmeterol/fluticasone.
    Hojo M; Iikura M; Hirashima J; Suzuki M; Sugiyama H
    Allergol Int; 2014 Mar; 63(1):103-11. PubMed ID: 24569153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Haruta Y; Hozawa M
    Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
    Lötvall J; Langley S; Woodcock A
    Respir Res; 2006 Aug; 7(1):110. PubMed ID: 16919161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
    Ankerst J
    J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
    Snowise NG; Clements D; Ho SY; Follows RM
    Curr Med Res Opin; 2013 Dec; 29(12):1663-74. PubMed ID: 24010736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
    Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
    Price DB; Williams AE; Yoxall S
    Respir Res; 2007 Jul; 8(1):46. PubMed ID: 17610727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.